157 related articles for article (PubMed ID: 35844300)
1. Chimeric antigen receptor T-cell therapy: Challenges and framework of outpatient administration.
Gatwood KS; Dholaria BR; Lucena M; Baer B; Savani BN; Oluwole OO
EJHaem; 2022 Jan; 3(Suppl 1):54-60. PubMed ID: 35844300
[TBL] [Abstract][Full Text] [Related]
2. Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations.
Gatwood K; Mahmoudjafari Z; Baer B; Pak S; Lee B; Kim H; Abernathy K; Dholaria B; Oluwole O
Clin Hematol Int; 2024; 6(2):11-20. PubMed ID: 38817307
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
Cummins KD; Gill S
Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
[TBL] [Abstract][Full Text] [Related]
4. Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas.
El-Galaly TC; Cheah CY; Kristensen D; Hutchison A; Hay K; Callréus T; Villa D
Acta Oncol; 2020 Jul; 59(7):766-774. PubMed ID: 32189546
[No Abstract] [Full Text] [Related]
5. CRISPR Takes the Front Seat in CART-Cell Development.
Manriquez-Roman C; Siegler EL; Kenderian SS
BioDrugs; 2021 Mar; 35(2):113-124. PubMed ID: 33638865
[TBL] [Abstract][Full Text] [Related]
6. Sepsis Care Pathway 2019.
Labib A
Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
[No Abstract] [Full Text] [Related]
7. The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy.
Schubert ML; Rohrbach R; Schmitt M; Stein-Thoeringer CK
Front Immunol; 2021; 12():670286. PubMed ID: 34135898
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Outpatient versus Inpatient Administration of CAR-T Therapies on Clinical, Economic, and Humanistic Outcomes in Patients with Hematological Cancer: A Systematic Literature Review.
Hansen DK; Liu YH; Ranjan S; Bhandari H; Potluri R; McFarland L; De Braganca KC; Huo S
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136292
[TBL] [Abstract][Full Text] [Related]
9. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Lyman GH; Nguyen A; Snyder S; Gitlin M; Chung KC
JAMA Netw Open; 2020 Apr; 3(4):e202072. PubMed ID: 32250433
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health.
Banerjee R; Shah N; Dicker AP
JCO Clin Cancer Inform; 2021 Jun; 5():668-678. PubMed ID: 34110929
[TBL] [Abstract][Full Text] [Related]
12. Bridging Radiation Therapy Before Commercial Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Aggressive B-Cell Lymphoma.
Wright CM; LaRiviere MJ; Baron JA; Uche C; Xiao Y; Arscott WT; Anstadt EJ; Barsky AR; Miller D; LaRose MI; Landsburg DJ; Svoboda J; Nasta SD; Gerson JN; Barta SK; Chong EA; Schuster SJ; Paydar I; Maity A; Plastaras JP
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):178-188. PubMed ID: 32446950
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy.
Stock S; Schmitt M; Sellner L
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835562
[TBL] [Abstract][Full Text] [Related]
14. Impact of transitioning inpatient chemotherapy regimens to the outpatient setting.
Corsi MP; Shea K; W Knoebel R
J Oncol Pharm Pract; 2020 Sep; 26(6):1324-1330. PubMed ID: 31822200
[TBL] [Abstract][Full Text] [Related]
15. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation.
Holland EM; Molina JC; Dede K; Moyer D; Zhou T; Yuan CM; Wang HW; Stetler-Stevenson M; Mackall C; Fry TJ; Panch S; Highfill S; Stroncek D; Little L; Lee DW; Shalabi H; Yates B; Shah N
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35534047
[TBL] [Abstract][Full Text] [Related]
17. The clinical study on treatment of CD19-directed chimeric antigen receptor-modified T cells in a case of refractory Richter syndrome.
Xia L; Wang Y; Li T; Hu X; Chen Q; Liu L; Jiang B; Li C; Wang H; Wang S; Yang G; Bao Y
Cancer Med; 2019 Jun; 8(6):2930-2941. PubMed ID: 31050207
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
19. Toxicities associated with adoptive cellular therapies.
Hansen DK; Dam M; Faramand RG
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101287. PubMed ID: 34625233
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]